Science Links Japan | Multimodality therapy with standard cisplatin and protracted infusion of 5-fluorouracil with concurrent hyperfractionated radiation in locally advanced esophageal cancer patients.

Multimodality therapy with standard cisplatin and protracted infusion of 5-fluorouracil with concurrent hyperfractionated radiation in locally advanced esophageal cancer patients.

Accession number;00A0593240

Title;Multimodality therapy with standard cisplatin and protracted infusion of 5-fluorouracil with concurrent hyperfractionated radiation in locally advanced esophageal cancer patients.

Author; OSAWA HIROSHI (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) INAMOTO YUKIO (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) AIBA KEISUKE (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) HORIKOSHI NOBORU (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) YAMASHITA TAKASHI (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) UEDA MAMORU (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.) MATSUBARA TOSHIKI (Cancer Inst. Hosp., Jpn. Found. for Cancer Res.)

Journal Title;Japanese Journal of Chemotherapy

Journal Code:F0608A

ISSN:1340-7007

VOL.48;NO.5;PAGE.341-346(2000)

Figure&Table&Reference;TBL.2, REF.22

Pub. Country;Japan

Language;Japanese

Abstract;[Purpose] To determine the efficacy and toxicity of chemotherapy consisiting of cisplatin (CDDP) and protracted infusion of 5-fluorouracil(5-FU) and concurrent hyperfractionated radiation(RT) as preoperative therapy in patients strictly diagnosed as having locally advanced esophageal cancer. [Patients and Methods] Patients, who had been diagnosed with T4 in the TNM classification with measurable lesions, were eligible for this study. CDDP was administered intravenously at a dose of 75mg/m2/day over 2 hours on day 1, protracted intravenous infusion of 5-FU was performed at a dose of 300mg/m2/day, followed by RT at a dose of 2 Gray/2 fractions/day for days 2-29. After four weeks of rest, total esophagectomy with three-field lymph node dissection was performed. [Results] Twenty patients were enrolled in this study. All were evaluable for response and toxicity, and operations were performed for all patients. One pathological CR (5%) and 8 PRs (40%), among the 20 patients, were obtained. The median disease-free interval and the median overall survival were 10.5 and 22.5 months, respectively. There was a statistically significant difference in the disease-free interval between the patients who had post-operative adjuvant therapy and those who did not (p=0.03). The major side effects were leukopenia, neutropenia, gastrointestinal toxicity and esophagitis. These toxicities were generally mild. [Conclusions] The response rate appears to be the same as those of other therapies reported previously for advanced esophageal cancer. Though the utility of adjuvant therapy has been questionable in the literature, our data suggest that not only pre-operative chemoradiotherapy but also the post-operative adjuvant therapy improve survival for patients with locally advanced esophageal cancer. (author abst.)

Related Articles;